Skip to main content
Moberg Pharma logo

Moberg Pharma — Investor Relations & Filings

Ticker · MOB ISIN · SE0020353928 LEI · 549300XFXK7DVGDRP410 ST Manufacturing
Open in API
Filings indexed 785 across all filing types
Latest filing 2024-06-28 Declaration of Voting R…
Country SE Sweden
Listing ST MOB

About Moberg Pharma

https://www.mobergpharma.com/

Moberg Pharma is a pharmaceutical company that develops and commercializes proprietary medical products, focusing on innovative drug delivery of proven compounds. The company's primary asset is MOB-015, a topical formulation for the treatment of onychomycosis (nail fungus). MOB-015 has demonstrated high fungal cure rates in Phase 3 clinical trials and has received market approval in multiple European countries. It is commercialized under the brand name Terclara® in Sweden and Norway, where it has achieved market leadership. Moberg Pharma's business model aims for lower development risk and faster market entry than traditional pharmaceutical development. The company's strategic goal is to establish MOB-015 as the leading global treatment for nail fungus.

Recent filings

Filing Released Lang Actions
Förändring av antalet aktier och röster i Moberg Pharma AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document explicitly announces a change in the total number of outstanding shares and votes due to the exercise of warrants (TO 2) and the issuance/conversion of C-shares. This directly relates to changes in the company's capital structure, specifically the number of shares. This aligns perfectly with the definition of 'Share Issue/Capital Change' (SHA). Although it involves warrants, the core announcement is the resulting change in the total share count, making SHA more specific than Capital/Financing Update (CAP) or Transaction in Own Shares (POS), as it details the final count resulting from these actions.
2024-06-28 Swedish
Moberg Pharma tillförs 336 MSEK genom TO 2 och riktad nyemission till toppgaranter – teckningsgraden i TO 2 blev 98%
Capital/Financing Update Classification · 98% confidence The document is a press release dated June 24, 2024, announcing the successful completion of a financing event involving the exercise of warrants (TO 2) and a directed new share issue (Nyemissionen) to top guarantors. The core subject is the inflow of capital (336 MSEK) resulting from these actions, which directly relates to the company's capital structure and fundraising activities. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it details a specific capital transaction.
2024-06-24 Swedish
Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors – subscription rate in TO 2 of 98%
Capital/Financing Update Classification · 99% confidence The document is a press release dated June 24th, 2024, announcing the financial outcome of the exercise of warrants (TO 2) and a directed share issue to top guarantors, resulting in the company receiving approximately SEK 336 million. This activity directly relates to changes in the company's capital structure, fundraising, and the issuance of new shares. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it details a specific financing event.
2024-06-24 English
The last day for trading in Moberg Pharma's warrants of series 2023:1 (TO 2) is today, June 17[th], 2024
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated June 17th, 2024, announcing that it is the last day for trading in specific warrants (TO 2) related to a previous rights issue. It details the exercise period, subscription price, potential issue proceeds (SEK 326.4 million), and subsequent capital increase scenarios. This content directly relates to changes in the company's capital structure, financing terms, and the mechanics of exercising securities, which aligns best with the 'Capital/Financing Update' category. It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), but a specific announcement about capital instruments.
2024-06-17 English
Sista dag för handel i Moberg Pharmas teckningsoptioner av serie 2023:1 (TO 2) är idag, den 17 juni 2024
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated June 17, 2024, announcing that it is the last day for trading in Moberg Pharma's warrants (TO 2) and detailing the exercise period and subscription price. The content focuses entirely on the mechanics and timeline of exercising warrants related to a previous rights issue. This is a specific corporate action related to capital structure and financing instruments, but it is not a formal regulatory filing like a 10-K or a general earnings release. Since it deals directly with the issuance/exercise of options/warrants, it fits best under 'Capital/Financing Update' (CAP). It is not a general regulatory announcement (RNS) because it is highly specific to a financing event, nor is it a general announcement of a report (RPA).
2024-06-17 Swedish
Moberg Pharma has secured exercise of warrants and entered into a top guarantee free of charge
Capital/Financing Update Classification · 98% confidence The document is a press release dated June 11th, 2024, announcing that Moberg Pharma has secured commitments related to the exercise of warrants (TO 2) and entered into a top guarantee commitment. This action directly concerns the company's financing activities, capital structure, and the potential issuance of new shares based on existing warrants. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP), which covers fundraising and capital structure changes. It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV).
2024-06-11 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.